| Literature DB >> 26772960 |
Jia Shen1, Aaron W James2, Xinli Zhang1, Shen Pang3, Janette N Zara1, Greg Asatrian4, Michael Chiang4, Min Lee5, Kevork Khadarian3, Alan Nguyen4, Kevin S Lee4, Ronald K Siu4, Sotirios Tetradis6, Kang Ting7, Chia Soo8.
Abstract
The differentiation factor NEL-like molecule-1 (NELL-1) has been reported as osteoinductive in multiple in vivo preclinical models. Bone morphogenetic protein (BMP)-2 is used clinically for skeletal repair, but in vivo administration can induce abnormal, adipose-filled, poor-quality bone. We demonstrate that NELL-1 combined with BMP2 significantly optimizes osteogenesis in a rodent femoral segmental defect model by minimizing the formation of BMP2-induced adipose-filled cystlike bone. In vitro studies using the mouse bone marrow stromal cell line M2-10B4 and human primary bone marrow stromal cells have confirmed that NELL-1 enhances BMP2-induced osteogenesis and inhibits BMP2-induced adipogenesis. Importantly, the ability of NELL-1 to direct BMP2-treated cells toward osteogenesis and away from adipogenesis requires intact canonical Wnt signaling. Overall, these studies establish the feasibility of combining NELL-1 with BMP2 to improve clinical bone regeneration and provide mechanistic insight into canonical Wnt pathway activity during NELL-1 and BMP2 osteogenesis. The novel abilities of NELL-1 to stimulate Wnt signaling and to repress adipogenesis may highlight new treatment approaches for bone loss in osteoporosis.Entities:
Mesh:
Substances:
Year: 2016 PMID: 26772960 PMCID: PMC4729267 DOI: 10.1016/j.ajpath.2015.10.011
Source DB: PubMed Journal: Am J Pathol ISSN: 0002-9440 Impact factor: 4.307